July 24, 2017 / 11:43 AM / a month ago

BRIEF-Theratechnologies announces new findings with investigational Antiretroviral Ibalizumab, with EGRIFTA

July 24 (Reuters) - Theratechnologies Inc:

* Theratechnologies Inc - announces new findings with investigational Antiretroviral Ibalizumab and with EGRIFTA

* Phase IIb trial, TMB-202 data for ibalizumab show no significant difference in susceptibility in patient HIV isolates Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below